HK Stock Market Move | China Coal Energy (01898) rose nearly 4% with a slight decrease of 3.2% in net profit attributable to shareholders in the first quarter. Institutions are optimistic about the company's profit improvement.
China Coal Energy (01898) rose by nearly 4%, as of the time of writing, it rose by 3.89%, to HK$14.14, with a turnover of HK$224 million.
China Coal Energy (01898) rose nearly 4%, as of the end of the writing, rose 3.89% to HK$14.14, with a turnover of HK$224 million.
In terms of news, China Coal Energy released its first quarter performance for 2026, with operating income of approximately RMB 34.189 billion, a year-on-year decrease of 10.9%; net profit attributable to shareholders of listed companies was approximately RMB 3.844 billion, a year-on-year decrease of 3.2%. The announcement stated that in the first quarter, the company's coal business achieved operating income of RMB 26.39 billion, a year-on-year decrease of 15.6%. Among them: the sales revenue of self-produced coal was RMB 14.727 billion, a year-on-year decrease of 8.4%, mainly due to an increase in the sales price of self-produced coal by RMB 4/ton year-on-year, increasing revenue by RMB 1.19 billion; sales volume decreased by 2.98 million tons year-on-year, decreasing revenue by RMB 1.462 billion.
Guosen previously pointed out that in 2026, affected by reduced production of Indonesian coal and geopolitical conflicts, the price difference between oil and coal is expanding, and the profitability of the company's coal chemical and coal business is expected to significantly improve. The company's performance is expected to improve significantly, and with the production of projects under construction in 2026-2027, production growth is expected. Shenwan Hongyuan Group stated that it is optimistic about the lucrative prospects of coal chemical industry bringing about increased profits for the company.
Related Articles

J&T EXPRESS-W (01519) spent 23.4103 million Hong Kong dollars to repurchase 2.284 million shares on April 28th.

UNITED LAB (03933): TUL321 Capsules receive approval for new drug clinical trials by the US FDA.

LEGENDHOLDING (03396) will distribute a final dividend of 0.1 yuan per share on August 28th.
J&T EXPRESS-W (01519) spent 23.4103 million Hong Kong dollars to repurchase 2.284 million shares on April 28th.

UNITED LAB (03933): TUL321 Capsules receive approval for new drug clinical trials by the US FDA.

LEGENDHOLDING (03396) will distribute a final dividend of 0.1 yuan per share on August 28th.






